Cannvas MedTech (CSE:MTEC) (“Cannvas” or the “Company”) , a leading business technology company in the cannabis space, is pleased to announce the appointment of Steve Loutskou as CEO of Cannvas Cannabis Acquisitions Corp. (“Cannvas Cannabis”), a wholly-owned subsidiary with a focus on investment and acquisition in the expanding global cannabis sector.  Mr. Loutskou will remain Chief Operating Officer, Global Markets of the Company and will serve concurrently for both entities.

“Our new M&A subsidiary required a seasoned professional to strategically navigate the complex and fragmented cannabis markets and Steve is best suited for this position,” said Shawn Moniz, CEO of the Company.  “Steve’s extensive career identifying and developing high-growth businesses is a testament to his remarkable ability to recognize early-stage market opportunities and is complemented by his proven marketing, financial and technological expertise.  Cannvas and Cannvas Cannabis will work hand-in-hand to achieve the common goal of creating shareholder value, and with Steve’s proven leadership abilities, Cannvas Cannabis has a very bright future.”


Mr. Loutskou is an experienced multi-disciplinary innovator and has been at the forefront of integrative business application development. He founded FourOneSix, a consulting and advisory company that provides technology, marketing and growth strategy solutions to early and late-stage businesses. At FourOneSix, Mr. Loutskou managed a portfolio of business clients through the process of creating, promoting, and evolving their online footprint, and worked to ensure they engage in successful practices to reflect the ever-changing online market demands. He is also the founder and CEO of RidgePark.net, a boutique real estate investment and development company based in Toronto, Ontario.

“I’m proud of my successful track record of identifying early-stage business opportunities and developing and expanding companies from start-ups through to large and sustainable organizations,” said Steve Loutskou, CEO of Cannvas Cannabis and Chief Operating Officer, Global Markets at the Company.  “I look forward to exciting opportunities with Cannvas Cannabis as we explore the medical and adult-use cannabis industry to discover emerging trends, compelling stories and innovative products and services relevant to the global cannabis market.”

Cannvas Cannabis seeks to complement Cannvas’ current product offering through continuous development, strategic investments and acquisitions in the cannabis sector. Related companies may include, but are not limited to:

  • Technology
  • Marketing and design
  • Packaging
  • Food and nutraceuticals
  • Regulation and enforcement
  • New product development
  • Cultivation related equipment
  • Gear and paraphernalia
  • Retail stores & dispensaries
  • Testing labs

Cannabis research sources calculate legal pot sales in North America climbed approximately 33% in 2017 to almost $10 billion, and project annual sales will grow to $25 billion by 2021. In a 2017 study, Deloitte estimates the size of the ancillary cannabis market to be approximately 2.5 times the size of the actual cannabis cultivation market.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

For further information: www.cannvasmedtech.com; Media Inquiries: media@cannvasmedtech.com; Investor Relations: ir@cannvasmedtech.com, 1-800-489-0116

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation.

Source: www.newswire.ca

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less